Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

3TC approved: now for the tough questions.

Journal of the International Association of Physicians in AIDS Care - 1 Dec 1995

Mascolini M

Abstract excerpt

Three clinical investigators examine key questions on the use of 3TC/ZDV therapy for patients with HIV infection, including previously-untreated patients. Questions addressed are: 1) Is adding 3TC to the regimens of ZDV-experienced individuals as enticing a strategy as starting 3TC/ZDV in people who are anti-retroviral naive? 2) Will 3TC's in vitro cross-resistance with didanosine (ddI) and zalcitabine (ddC)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Zalcitabine
Share to Antiviral Agents
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Approval

Share to Drug Resistance, Microbial

Share to Drug Therapy, Combination

Share to Lamivudine

Share to Zidovudine

Source

Identifiers

PMID: 11363101

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

3TC approved: now for the tough questions.PMID 11363101Read ↗

FDA triple header. Food and Drug Administration.Semantic proximity Read ↗

The emergence of HIV resistance and new antiretrovirals: are we winning?Semantic proximity Read ↗

IDSA update from the city of brotherly love.Semantic proximity Read ↗

The medical merry-go-round: drugs for 1998 are new but not novel.Semantic proximity Read ↗

New weapons on the way in battle against mutating HIV.Semantic proximity Read ↗

New nonnucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.Semantic proximity Read ↗

Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudineSemantic proximity Read ↗

Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team.Semantic proximity Read ↗

A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?Semantic proximity Read ↗

Los Angeles, New York, Stanford University: HBY 097, new drug may weaken HIV.Semantic proximity Read ↗

3TC treatment may slow HIV mutations, development of drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.